Table. [18F]FluorThanatrace Uptake, Receptor, and Germline Pathogenic Variant Status .
| Patient identification No. (n = 30) | Maximum SUV, g/mL | Receptor | Germline status |
|---|---|---|---|
| 1 | 5.7 | ER+ | Negative |
| 2 | 6.9 | ER+ | Negative |
| 3 | 4.5 | TNBC | Negative |
| 4 | 9.2 | HER2+ | Negative |
| 5 | 6.0 | ER+ | Negative |
| 6 | 7.1 | ER+ | Negative |
| 7 | 4.0 | ER+ | Negative |
| 8 | 5.7 | ER+ | Negative |
| 9 | 6.5 | TNBC | BRCA1 positive |
| 10 | 4.3 | ER+ | Negative |
| 11 | 4.4 | HER2+ | CHEK2 positive |
| 12 | 5.6 | HER2+ | Negative |
| 13 | 4.5 | HER2+ | Negative |
| 14 | 8.0 | TNBC | Negative |
| 15 | 3.7 | HER2+ | Negative |
| 16 | 6.6 | TNBC | Negative |
| 17 | 2.6 | TNBC | CHEK2 positive |
| 18 | 5.1 | TNBC | BRCA1 positive |
| 19 | 2.9 | TNBC | BRCA2 positive |
| 20 | 6.9 | ER+ | Negative |
| 21 | 11.3 | TNBC | BRCA2 positive |
| 22 | 6.5 | ER+ | Negative |
| 24 | 2.9 | TNBC | Negative |
| 25 | 9.1 | ER+ | Negative |
| 26 | 4.8 | HER2+ | Negative |
| 28 | 9.6 | TNBC | BRCA2 positive |
| 29 | 4.4 | ER+ | BRCA2 positive |
| 30 | 2.7 | ER+ | Negative |
| 31 | 7.9 | TNBC | Negative |
| 32 | 6.2 | TNBC | Negative |
Abbreviations: ER+, estrogen receptor–positive; HER2+, human epidermal growth factor receptor 2–positive; SUV, standardized uptake value; TNBC, triple negative breast cancer.